Literature DB >> 12214727

The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases.

A Gadducci1, E Sartori, F Landoni, P Zola, T Maggino, S Cosio, G Tisi, A Lissoni, A M Ferrero, R Cristofani.   

Abstract

PURPOSE OF INVESTIGATION: The objective of this retrospective multicenter study was to assess the prognostic relevance of histologic type in uterine sarcomas.
METHODS: The hospital reports of 249 patients with uterine sarcomas were reviewed. Surgery was the initial therapy for all patients. Histologic type was leiomyosarcoma in 95 cases, low-grade endometrial stromal sarcoma (ESS) in 19, high-grade ESS in 34, and carcinosarcoma in 101. Postoperative treatment was given without well-defined protocols. Median follow-up of survivors was 97 months.
RESULTS: In the whole series 2-year, 5-year, and 10-year survival rates were 53.5%, 41.6%, and 35.8%, respectively, and median survival was 31 months. At univariate analysis survival was significantly related to stage (p = 0.0001), mitotic count (p = 0.0001), and histologic type (low-grade ESS vs leiomyosarcoma vs carcinosarcoma vs high-grade ESS, median: not reached vs 27 months vs 21 months vs 16.5 months, p = 0.0011), but not to postoperative therapy and patient age. The Cox model revealed that tumor stage, mitotic count and histologic type were independent prognostic variables for survival. In detail, the risk of death was significantly lower for low-grade ESS (risk ratio [RR] = 0.257; 95% confidence interval [CI] = 0.071-0.931) and carcinosarcoma (RR = 0.509; 955 CI = 0.324-0.799) when compared to leiomyosarcoma. Conversely, no significant difference in survival was found between leiomyosarcoma and high-grade ESS.
CONCLUSIONS: Histologic type is an independent prognostic variable for survival in uterine sarcomas. Low-grade ESS has the best clinical outcome, whereas leiomyosarcoma has the poorest one. It is noteworthy that, when adjusting for stage and mitotic count, leiomyosarcoma has a significantly worse prognosis than carcinosarcoma.

Entities:  

Mesh:

Year:  2002        PMID: 12214727

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  11 in total

1.  A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.

Authors:  H J Mackay; R J Buckanovich; H Hirte; R Correa; P Hoskins; J Biagi; L P Martin; G F Fleming; R Morgan; L Wang; R Polintan; A M Oza
Journal:  Gynecol Oncol       Date:  2011-12-02       Impact factor: 5.482

2.  A predictive diagnostic model using multiparametric MRI for differentiating uterine carcinosarcoma from carcinoma of the uterine corpus.

Authors:  Yuki Kamishima; Mitsuru Takeuchi; Tatsuya Kawai; Takatsune Kawaguchi; Ken Yamaguchi; Naoki Takahashi; Masato Ito; Toshinao Arakawa; Akiko Yamamoto; Kazushi Suzuki; Masaki Ogawa; Moe Takeuchi; Yuta Shibamoto
Journal:  Jpn J Radiol       Date:  2017-06-05       Impact factor: 2.374

3.  Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.

Authors:  Kenichi Harano; Akihiro Hirakawa; Mayu Yunokawa; Toshiaki Nakamura; Toyomi Satoh; Tadaaki Nishikawa; Daisuke Aoki; Kimihiko Ito; Kiyoshi Ito; Toru Nakanishi; Nobuyuki Susumu; Kazuhiro Takehara; Yoh Watanabe; Hidemichi Watari; Toshiaki Saito
Journal:  Int J Clin Oncol       Date:  2015-06-18       Impact factor: 3.402

Review 4.  Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.

Authors:  Khadra Galaal; Keith Godfrey; Raj Naik; Ali Kucukmetin; Andrew Bryant
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

Review 5.  Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.

Authors:  Khadra Galaal; Esther van der Heijden; Keith Godfrey; Raj Naik; Ali Kucukmetin; Andrew Bryant; Nagindra Das; Alberto D Lopes
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

6.  Carcinosarcoma of the uterus-a single institution retrospective analysis of the management and outcome and a brief review of literature.

Authors:  Rajanbabu Anupama; Santhosh Kuriakose; D K Vijaykumar; K Pavithran; Annie Jojo; R Nair Indu; V S Sheejamol
Journal:  Indian J Surg Oncol       Date:  2013-01-27

7.  Uterine leiomyosarcoma: A case report.

Authors:  Khushpreet Kaur; Parneet Kaur; Arvinder Kaur; Atish Singla
Journal:  J Midlife Health       Date:  2014-10

8.  Rare Endobronchial metastasis from uterine leiomyosarcoma.

Authors:  Saswata Ghosh; Susmita Kundu; Amitava Pal; Suman Paul
Journal:  Lung India       Date:  2015 Mar-Apr

9.  Outcome and Predictive Factors in Uterine Carcinosarcoma Using Postoperative Radiotherapy: A Rare Cancer Network Study.

Authors:  Daniel R Zwahlen; Ulrike Schick; Yasemin Bolukbasi; Juliette Thariat; Roxolyana Abdah-Bortnyak; Abraham Kuten; Sefik Igdem; Hale Caglar; Zeynep Ozsaran; Kristina Loessl; Kaouthar Khanfir Belkaaloul; Sylviane Villette; Hansjörg Vees
Journal:  Rare Tumors       Date:  2016-06-29

10.  Outcomes of carcinosarcoma in a tertiary care institution in India.

Authors:  Anne George Cherian; Anitha Thomas; Ajit Sebastian; Tunny Sebastian; Vinotha Thomas; Rachel G Chandy; Abraham Peedicayil
Journal:  South Asian J Cancer       Date:  2018 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.